SCHEMBL2611908

SCHEMBL2611908

CC(C)(C)OC(=O)[C@H](N)CC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.36
NOS1 P29475 2/20 0.36
NOS3 P29474 1/20 0.36
NOS2 P35228 1/20 0.36
SLC7A5 Q01650 1/20 0.36
GRIK1 P39086 1/20 0.35
DGAT1 O75907 1/20 0.34
PGD P52209 1/20 0.34
BHMT Q93088 1/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 1/20 0.33
GABRR1 P24046 2/20 0.32
LMNA P02545 1/20 0.32
SLC22A6 Q4U2R8 1/20 0.32
AAK1 Q2M2I8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL330114 1.00 LTA4H (0.36) LTA4HNOS1NOS3NOS2SLC7A5
SCHEMBL375959 1.00 LTA4H (0.36) LTA4HNOS1NOS3NOS2SLC7A5
Water SCHEMBL30283282 0.98 LTA4H (0.36) LTA4HNOS1NOS3NOS2SLC7A5
Hydrochloric Acid SCHEMBL6700549 0.98 LTA4H (0.36) LTA4HNOS1NOS3NOS2SLC7A5
Hydrochloric Acid SCHEMBL6700554 0.98 LTA4H (0.36) LTA4HNOS1NOS3NOS2SLC7A5
Hydrochloric Acid SCHEMBL25276889 0.98 LTA4H (0.36) LTA4HNOS1NOS3NOS2SLC7A5
SCHEMBL28833837 0.98 LTA4H (0.36) LTA4HNOS1NOS3NOS2SLC7A5
Hydrochloric Acid SCHEMBL30947817 0.86 KDM4E (0.38) GRIK1PGDBHMTGABRR1LMNA
SCHEMBL17732318 0.86 PGD (0.37) GRIK1PGDBHMTGABRR1LMNA
SCHEMBL29720991 0.85 DGAT1 (0.34) NOS1NOS3NOS2SLC7A5GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317780-A1 RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF Technische Universität München (DE) 2024-09-26 US disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 EP disclosed
US-20240115553-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY AZEVAN PHARMACEUTICALS, INC. (US) 2024-04-11 US disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 US disclosed
CN-117320759-A Radiopharmaceutical somatostatin receptor ligands and precursors thereof 慕尼黑工业大学 2023-12-29 CN disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 WO disclosed
US-20220283131-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS CO., LTD. (KR) 2022-09-08 US disclosed
US-11319306-B2 Compositions and methods for treating neurodegenerative diseases AZEVAN PHARMACEUTICALS, INC. (US) 2022-05-03 US disclosed
WO-2022050529-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE ㈜베르티스 2022-03-10 WO disclosed
EP-2414319-B1 NICOTIANAMINE-DERIVED METALLOPHORE AND PROCESSES FOR PRODUCING SAME COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2015-07-01 EP disclosed
US-8563280-B2 Nicotianamine-derived metallophore and processes for producing same COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2013-10-22 US disclosed
US-8563280-B2 Nicotianamine-derived metallophore and processes for producing same COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2013-10-22 US disclosed
US-20120095262-A1 Nicotianamine-Derived Metallophore And Processes For Producing Same CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-04-19 US disclosed
US-20120095262-A1 Nicotianamine-Derived Metallophore And Processes For Producing Same CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-04-19 US disclosed
WO-2010112697-A1 NICOTIANAMINE-DERIVED METALLOPHORE AND PROCESSES FOR PRODUCING SAME COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2010-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095262-A1 Nicotianamine-Derived Metallophore And Processes For Producing Same NIT2, NNMT, NQO1 LTA4H 1044/4885NOS1 249/4885NOS3 561/4885
US-20240115553-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY FABP7, PYGB, CHAT LTA4H 927/4885NOS1 848/4885NOS3 185/4885
US-11319306-B2 Compositions and methods for treating neurodegenerative diseases HTT, AVPR2, AVPR1B LTA4H 1747/4885NOS1 1389/4885NOS3 1270/4885
US-20240317780-A1 RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF SSTR1, SSTR3, SSTR4 LTA4H 4059/4885NOS1 2793/4885NOS3 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.